ADVERTISEMENT

What Stage Is Your Breast Cancer?

A guide to how breast cancers are staged, from in situ (stage 0) to metastatic (stage IV).

$author$
PUBLISHED FRIDAY, APRIL 20, 2007
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.

Breast cancer is staged based on the size of the tumor and if and where it has spread, including nearby lymph nodes or distant organs of the body. Staging is defined as TNM: T for tumor size (0 to 4); N for lymph node involvement (0 to 3); M for whether the cancer has spread, or metastasized, to distant organs (0 or 1). Once these attributes have been determined, an overall stage of 0, 1, 2, 3 or 4 (also written as Roman numerals) is assigned.

Stage 0: About 62,000 women will be diagnosed this year with what is called in situ breast cancer—abnormal cells that have not spread from the milk ducts or lobules. Ductal carcinoma in situ is cancerous cells contained within the milk ducts, usually treated with breast-conserving surgery and radiation, or mastectomy. Lobular carcinoma in situ is when precancerous cells are contained in the lobes. Women with LCIS are at high risk for invasive cancer and may be prescribed tamoxifen to prevent further development of the abnormal cells and are advised to increase the frequency of clinical exams.

Stage 1: The tumor measures less than 2 centimeters. Although cancer cells have invaded the fatty or connective tissue, the cancer has not spread outside the breast. Breast-conserving surgery or mastectomy, along with an examination of nearby lymph nodes for errant cancer cells is recommended treatment.

Stage 2A: Tumors can be as large as 5 centimeters without lymph node involvement or less than 2 centimeters but has spread to nearby lymph nodes underneath the arm (called axillary nodes).

Stage 2B: The tumor is between 2 and 5 centimeters and cancer cells have invaded one to three nearby nodes. The tumor can be larger than 5 centimeters as long as it has not invaded axillary nodes.

Stage 3A: The tumor is smaller than 5 centimeters, but has spread to four to nine axillary nodes, which have grown together or into other nearby structures; or the cancer is larger than 5 centimeters and has spread to one to nine axillary nodes.

Stage 3B: The tumor has extended into the chest wall, skin or the ribs and may have spread to no lymph nodes or to as many as nine axillary nodes. It may have spread to internal mammary lymph nodes found on the inside of the chest along the breast bone.

Stage 3C: The cancer has spread to the lymph nodes located above the collarbone and at the base of the neck, or to 10 or more axillary nodes. Inflammatory breast cancer is classified as stage 3 unless it has spread to distant sites, which moves its classification to stage 4.

Stage 4: Cancer cells have traveled to distant nodes and organs of the body, including the brain, lung or liver; considered metastatic breast cancer.

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
Related Articles
Telephone Intervention Helps Breast Cancer Survivors Set—and Meet—Lifestyle Goals
BY CHRISTINA IZZO
A new telephone-based intervention for breast cancer survivors is showing promise, and it involves them becoming more actively engaged in goal setting and problem solving with an eye toward accelerating their recovery by engaging in health-promoting activities such as exercise, stress management and healthy eating.
Diabetes May Predispose Women to More Advanced Breast Cancer
BY CHRISTINA IZZO
Breast cancer patients with diabetes were significantly more likely to be diagnosed with advanced-stage breast cancer than those without diabetes.
Crossing Tumor Types: BRCA Experience Points Way to New Diagnostic Paradigm
BY MAURIE MARKMAN, MD
It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.
Is Immunotherapy Ready for Prime Time in Breast Cancer?
BY ANDREW D. SMITH
Elizabeth A. Mittendorf, associate professor of surgical oncology at The University of Texas MD Anderson Cancer Center, discusses the progress and potential of immunotherapy in breast cancer treatment.
Angelina Jolie, Knowledge Is Not Enough
Two years ago, Angelina Jolie Pitt told the world that she held the BRCA1 mutation.
Related Videos
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
Medical Updates from the 32nd Annual Miami Breast Cancer Conference
The evolution of the treatment for hormone receptor-positive breast cancer was a hot topic for this year's Miami Breast Cancer Conference. Debu Tripathy, CURE's editor-in-chief and breast oncologist, reports from the meeting.
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$